Ladiratuzumab vedotin - CAS 1629760-29-7 Catalog number: BADC-01597

Ladiratuzumab vedotin is an antibody-drug conjugate (ADC) that combines a monoclonal antibody targeting the protein trophoblast cell-surface antigen 2 (Trop-2) with the cytotoxic agent monomethyl auristatin E (MMAE). Trop-2 is a cell surface glycoprotein overexpressed in several cancers, including breast, ovarian, and gastric cancers. The antibody component of Ladiratuzumab vedotin selectively binds to Trop-2 on cancer cells, allowing the drug to be specifically delivered to tumor sites. Upon internalization, the MMAE payload is released, which inhibits microtubule polymerization, resulting in cell cycle arrest and cell death. This targeted delivery mechanism minimizes damage to healthy cells, reducing systemic toxicity compared to traditional chemotherapy.

A significant application of Ladiratuzumab vedotin is in the treatment of metastatic triple-negative breast cancer (TNBC). TNBC is an aggressive subtype of breast cancer that lacks targeted therapies due to the absence of estrogen, progesterone, and HER2 receptors. Because Trop-2 is frequently overexpressed in TNBC, Ladiratuzumab vedotin can specifically target these cancer cells. Clinical trials have shown that Ladiratuzumab vedotin can improve progression-free survival in patients with heavily pre-treated TNBC, offering a promising therapeutic option for patients who do not respond to conventional treatments.

Ladiratuzumab vedotin is also being evaluated for its potential in the treatment of other Trop-2-expressing cancers, including ovarian and bladder cancers. For ovarian cancer, where Trop-2 is often overexpressed, Ladiratuzumab vedotin could provide a novel treatment option for patients with relapsed or resistant disease. Similarly, for urothelial carcinoma (bladder cancer), which has high Trop-2 expression, this ADC could target and deliver MMAE directly to tumor cells, improving treatment efficacy while reducing off-target effects. Its ability to target Trop-2 in a variety of solid tumors makes Ladiratuzumab vedotin a promising candidate for broader oncological applications.

In addition to its monotherapy potential, Ladiratuzumab vedotin is being explored in combination with other cancer therapies to enhance its therapeutic effect. Researchers are investigating its use alongside immune checkpoint inhibitors, chemotherapy, and targeted agents to improve response rates and overcome resistance mechanisms. By combining Ladiratuzumab vedotin with other agents, the aim is to create a synergistic treatment approach that not only targets the cancer more effectively but also stimulates the immune system to mount a stronger response against the tumor. This approach could significantly benefit patients with advanced cancers, improving survival outcomes and quality of life.